News
Jefferies London Healthcare Conference – Presentation
37th Annual Meeting Society for Immunotherapy of Cancer (SITC) 2022 – Abstracts
Abstract Number 1103 Half-life extended, conditionally active IFNa prodrug induces tumor-selective activation and potent antitumor response Abstract Number 1191 STRO-003 is a novel ROR1-targeted ADC for breast and lung cancer Abstract Number 1359...
Credit Suisse 31st Annual Healthcare Conference – Presentation
Sutro Biopharma Reports Third Quarter 2022 Financial Results, Business Highlights and Select Anticipated Milestones
- STRO-002 data demonstrating anti-leukemic activity in pediatric patients with relapsed/refractory CBF2AT3-GLIS2 AML are accepted for oral presentation at ASH 2022 - - STRO-002 data from the Phase 1 ovarian cancer dose-expansion cohort and the trial design of the...
64th American Society of Hematology Annual Meeting and Exposition – Abstract
Sutro Biopharma Announces Oral Presentation at the 64th American Society of Hematology Annual Meeting and Exposition
--Results from compassionate use program highlight promising activity of STRO-002 in children with rare form of acute myeloid leukemia, that is highly refractory to all standard-of-care therapies-- SOUTH SAN FRANCISCO, Calif., November 3, 2022 – Sutro Biopharma, Inc....
Sutro Biopharma to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., November 2, 2022 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive...
Sutro Biopharma Announces Departure of Chief Medical Officer
SOUTH SAN FRANCISCO, Calif., October 24, 2022 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Chief Medical Officer, Arturo...
2022 Wells Fargo Healthcare Conference – Presentation
Sutro Biopharma to Present at the 2022 Wells Fargo Healthcare Conference
SOUTH SAN FRANCISCO, Calif., September 1, 2022 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive...